UPDATE 4-Biogen/Eisai Alzheimer's drug cuts cognitive decline 30 pct -study [Reuters]
Biogen Inc. (BIIB)
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
biogen.com/en_us/investors.html
Company Research
Source: Reuters
Biogen/Eisai Alzheimer's drug cuts cognitive decline 30 percent: study | Reuters 5 Min Read CHICAGO (Reuters) - Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer’s disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than those who got a placebo in a highly anticipated mid-stage trial. The second-highest dose of the drug also showed some benefit, but did not meet statistical significance, according to data presented on Wednesday at the Alzheimer’s Association International Conference in Chicago. Investors, who had bid up Biogen and Eisai shares earlier this month after the companies said the drug was effective at the highest dose, were selling off shares after presentation of the details. Biogen shares fell more than 11 percent in extended trading to $339. Eisai fell as much as 20 percent on Thursday morning and was among the most actively traded stocks in Tokyo. The shares had touched a record high of 11,490 yen
Show less
Read more
Impact Snapshot
Event Time:
BIIB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIIB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
News
- CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug [Yahoo! Finance]Yahoo! Finance
- Biogen Inc. (BIIB) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Biogen Inc. (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $340.00 price target on the stock.MarketBeat
- Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor a [Yahoo! Finance]Yahoo! Finance
- Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsBusiness Wire
BIIB
Earnings
- 2/14/24 - Miss
BIIB
Sec Filings
- 2/26/24 - Form 4
- 2/22/24 - Form 144
- 2/21/24 - Form 4
- BIIB's page on the SEC website